ANAVEX®2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome

Rett syndrome (RTT) is a severe neurodevelopmental disorder that is associated in most cases with mutations in the transcriptional regulator MECP2. At present, there are no effective treatments for the disorder. Despite recent advances in RTT genetics and neurobiology, most drug development programs...

Full description

Saved in:

Bibliographic Details
Published in:	Pharmacology, biochemistry and behavior Vol. 187; p. 172796
Main Authors:	Kaufmann, Walter E., Sprouse, Jeffrey, Rebowe, Nell, Hanania, Taleen, Klamer, Daniel, Missling, Christopher U.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.12.2019
Subjects:	Animal models Animals Apnea - drug therapy Behavioral screening Body Weight - drug effects Disease Models, Animal Drug screening Female Furans - administration & dosage Furans - pharmacology Furans - therapeutic use Mecp2 deficiency Methyl-CpG-Binding Protein 2 - genetics Mice Mice, Inbred C57BL Mice, Transgenic Motor Skills - drug effects Neuroprotective Agents - administration & dosage Neuroprotective Agents - pharmacology Neuroprotective Agents - therapeutic use Receptors, sigma - agonists Reflex, Startle - drug effects Rett syndrome Rett Syndrome - drug therapy Rotarod Performance Test Sigma-1 Receptor Treatment Outcome Visual Acuity - drug effects Mecp2 deficiency Animal models Behavioral screening Drug screening Sigma-1 receptor Rett syndrome
ISSN:	0091-3057, 1873-5177, 1873-5177
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!